Takeda Collaborates with Charles River to Identify and Develop Preclinical Candidates

Shots:

• Charles River to receive up front, up to $50M as development milestones/ program, up to $120M as commercial milestones and royalties on net sales of the developed products.
• Takeda to launch multiple integrated programs targeting its four core therapeutic areas (oncology, gastroenterology, neuroscience, and rare disease) and will get an option to advance the preclinical candidates via their clinical development pipeline
•  The agreement combines Charles’ drug discovery expertise and deep scientific bench with Takeda’s investments in human data and translation to deliver transformative therapies to the needy patients

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Pinterest